Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy

FASEB Journal

Volumn 29, Issue 11, 2015, Pages 4461-4472

  Kramer, Rita ^a   Bielawski, Jacek ^a   Kistner Griffin, Emily ^a   Othman, Alaa ^b,c   Alecu, Irina ^b   Ernst, Daniela ^b   Kornhauser, Drew ^a   Hornemann, Thorsten ^b   Spassieva, Stefka ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF LÜBECK   (Germany)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

1 deoxyceramide; Chemotherapy; Serine palmitoyltransferase; Sphingolipid

Indexed keywords

1 DEOXYCERAMIDE; 1 DEOXYSPHINGOLIPID; ALANINE; CERAMIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FUMONISIN B1; PACLITAXEL; PHOSPHOGLYCERATE DEHYDROGENASE; SERINE; SERINE PALMITOYLTRANSFERASE; SERINE PALMITOYLTRANSFERASE LONG CHAIN BASE SUBUNIT 1; SERINE PALMITOYLTRANSFERASE LONG CHAIN BASE SUBUNIT 2; SPHINGOLIPID; UNCLASSIFIED DRUG; NEUROTOXIN;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CLINICAL ARTICLE; DISEASE SEVERITY; DNA CROSS LINKING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; ISOTOPE LABELING; LIPID BLOOD LEVEL; LIPID DEGRADATION; MASS SPECTROMETRY; MIDDLE AGED; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPHINGOLIPID METABOLISM; UPREGULATION; ADOLESCENT; BLOOD; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; HEK293 CELL LINE; MULTICENTER STUDY; TUMOR CELL LINE;

ADOLESCENT; ADULT; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HUMANS; MIDDLE AGED; NEUROTOXINS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; SPHINGOLIPIDS;

EID: 84949033367     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.15-272567     Document Type: Article

References (35)

1. Miltenburg, N. C., and Boogerd, W. (2014) Chemotherapyinduced neuropathy: a comprehensive survey. Cancer Treat. Rev. 40, 872-882
2. Hershman, D. L., Lacchetti, C., Dworkin, R.H., Lavoie Smith, E.M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., Paice, J., Schneider, B., Smith, M. L., Smith, T., Terstriep, S., Wagner-Johnston, N., Bak, K., and Loprinzi, C. L.; American Society of Clinical Oncology. (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 32, 1941-1967
3. Kaley, T. J., and Deangelis, L. M. (2009) Therapy of chemotherapyinduced peripheral neuropathy. Br. J. Haematol. 145, 3-14
4. Speck, R. M., Sammel, M. D., Farrar, J. T., Hennessy, S., Mao, J. J., Stineman, M.G., andDeMichele, A. (2013) Impact of chemotherapyinduced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J. Oncol. Pract. 9, e234-e240
5. Rowinsky, E. K., Chaudhry, V., Cornblath, D. R., and Donehower, R. C. (1993) Neurotoxicity of Taxol. J. Natl. Cancer Inst.Monogr. (15), 107-115
6. Loprinzi, C. L., Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K.N., Kamal, A., Le-Lindqwister, N.A., Soori, G. S., Jaslowski, A. J., Novotny, P. J., and Lachance, D. H. (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J. Clin. Oncol. 29, 1472-1478
7. Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., Kamal, A., Le-Lindqwister, N. A., Soori, G. S., Jaslowski, A. J., Kelaghan, J., Novotny, P. J., Lachance, D. H., and Loprinzi, C. L. (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118, 5171-5178
8. Schneider, B. P., Zhao, F., Wang, M., Stearns, V., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Jr., Wood, W. C., Davidson, N. E., and Sparano, J. A. (2012) Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J. Clin. Oncol. 30, 3051-3057
9. Lee, J. J., and Swain, S.M. (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 24, 1633-1642
10. Missmer, S. A., Suarez, L., Felkner, M., Wang, E., Merrill, A. H., Jr., Rothman, K. J., andHendricks, K. A. (2006) Exposure to fumonisins and the occurrence of neural tube defects along the Texas-Mexico border. Environ. Health Perspect. 114, 237-241
11. Shayman, J.A. (2014)Thematic reviewseries: Recent advances inthe treatment of lysosomal storage diseases. J. Lipid Res. 55, 993-994
12. Merrill, A. H., Jr. (2011) Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev. 111, 6387-6422
13. Penno, A., Reilly, M. M., Houlden, H., Laurá, M., Rentsch, K., Niederkofler, V., Stoeckli, E. T., Nicholson, G., Eichler, F., Brown, R. H., Jr., vonEckardstein, A., andHornemann, T. (2010)Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J. Biol. Chem. 285, 11178-11187
14. Rotthier, A., Auer-Grumbach, M., Janssens, K., Baets, J., Penno, A., Almeida-Souza, L., Van Hoof, K., Jacobs, A., De Vriendt, E., Schlotter-Weigel, B., Löscher, W., Vondráček, P., Seeman, P., De Jonghe, P., Van Dijck, P., Jordanova, A., Hornemann, T., and Timmerman, V. (2010) Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. Am. J. Hum. Genet. 87, 513-522
15. Rotthier, A., Penno, A., Rautenstrauss, B., Auer-Grumbach, M., Stettner, G.M., Asselbergh, B., VanHoof, K., Sticht, H., Lévy, N., Timmerman, V., Hornemann, T., and Janssens, K. (2011) Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I. Hum. Mutat. 32, E2211-E2225
16. Baird, R. D., Kitzen, J., Clarke, P. A., Planting, A., Reade, S., Reid, A., Welsh, L., López Lázaro, L., de lasHeras, B., Judson, I. R., Kaye, S. B., Eskens, F., Workman, P., deBono, J. S., and Verweij, J. (2009) Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol. Cancer Ther. 8, 1430-1437
17. Massard, C., Salazar, R., Armand, J. P., Majem, M., Deutsch, E., García, M., Oaknin, A., Fernández-García, E. M., Soto, A., and Soria, J. C. (2012) Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. Invest. New Drugs 30, 2318-2326
18. Schöffski, P., Dumez, H., Ruijter, R., Miguel-Lillo, B., Soto-Matos, A., Alfaro, V., and Giaccone, G. (2011) Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I doseescalating study in patients with advanced solidmalignancies. Cancer Chemother. Pharmacol. 68, 1397-1403
19. Auer-Grumbach, M. (2008) Hereditary sensory neuropathy type I. Orphanet J. Rare Dis. 3, 7
20. Bertea, M., Rütti, M. F., Othman, A., Marti-Jaun, J., Hersberger, M., von Eckardstein, A., and Hornemann, T. (2010) Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis. 9, 84
21. Bielawski, J., Pierce, J. S., Snider, J., Rembiesa, B., Szulc, Z.M., and Bielawska, A. (2010) Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/ MS). Adv. Exp. Med. Biol. 688, 46-59
22. Bielawski, J., Pierce, J. S., Snider, J., Rembiesa, B., Szulc, Z.M., and Bielawska, A. (2009)Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods Mol. Biol. 579, 443-467
23. Van Veldhoven, P. P., and Bell, R. M. (1988) Effect of harvesting methods, growth conditions and growth phase on diacylglycerol levels in cultured human adherent cells. Biochim. Biophys. Acta 959, 185-196
24. Othman, A., Rütti, M. F., Ernst, D., Saely, C. H., Rein, P., Drexel, H., Porretta-Serapiglia, C., Lauria, G., Bianchi, R., von Eckardstein, A., andHornemann, T. (2012) Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 55, 421-431
25. Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lantéri-Minet, M., Grant, R., Huddart, R., Moynihan, C., Maher, J., and Lucey, R.; EORTC Quality of Life Group. (2005) The development of an EORTCqualityof life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur. J. Cancer 41, 1135-1139
26. Kiya, T., Kawamata, T., Namiki, A., and Yamakage, M. (2011) Role of satellite cell-derivedL-serine inthe dorsal root ganglioninpaclitaxelinduced painful peripheral neuropathy. Neuroscience 174, 190-199
27. Rowinsky, E.K., Cazenave, L.A., andDonehower, R.C. (1990)Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82, 1247-1259
28. Cepeda, V., Fuertes, M. A., Castilla, J., Alonso, C., Quevedo, C., and Pérez, J.M. (2007)Biochemicalmechanisms of cisplatin cytotoxicity. Anticancer. Agents Med. Chem. 7, 3-18
29. Pewzner-Jung, Y., Ben-Dor, S., and Futerman, A.H. (2006)When do Lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J. Biol. Chem. 281, 25001-25005
30. Janes, K., Little, J.W., Li, C., Bryant, L., Chen, C., Chen, Z., Kamocki, K., Doyle, T., Snider, A., Esposito, E., Cuzzocrea, S., Bieberich, E., Obeid, L., Petrache, I., Nicol, G., Neumann, W. L., and Salvemini, D. (2014) The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. J. Biol. Chem. 289, 21082-21097
31. Babin, P. J., and Gibbons, G. F. (2009) The evolution of plasma cholesterol: direct utility or a "spandrel" of hepatic lipid metabolism? Prog. Lipid Res. 48, 73-91
32. Ksiazek, M., Chacinska, M., Chabowski, A., and Baranowski, M. (2015) Sources, metabolism and regulation of circulating sphingosine-1-phosphate [E-pub ahead of print]. J. Lipid Res. doi:10.1194/jlr.R059543
33. Eiseman, J. L., Eddington, N.D., Leslie, J., MacAuley, C., Sentz, D.L., Zuhowski, M., Kujawa, J. M., Young, D., and Egorin, M. J. (1994) Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother. Pharmacol. 34, 465-471
34. Seewaldt, V.L., Figge, D.C., Greer, B.E., Tamimi, H.K., Brown, W. S., and Cain, J. M. (1994) Primary central nervous system recurrence after paclitaxel therapy for epithelial ovarian malignancy. Gynecol. Oncol. 55, 456-458
35. Garofalo, K., Penno, A., Schmidt, B. P., Lee, H. J., Frosch, M. P., von Eckardstein, A., Brown, R. H., Hornemann, T., and Eichler, F. S. (2011) Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J. Clin. Invest. 121, 4735-4745